share_log

Genscript Biotech Insiders Sold US$11m Of Shares Suggesting Hesitancy

Genscript Biotech Insiders Sold US$11m Of Shares Suggesting Hesitancy

基因藥物研發服務商Genscript的內部人士出售了價值1100萬美元的股票,表明他們持幣觀望。
Simply Wall St ·  07/12 20:11

Over the past year, many Genscript Biotech Corporation (HKG:1548) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.

在過去的一年中,許多Genscript Biotech Corporation(HKG:1548)的內部人士出售了公司的大部分股份,這可能引起了投資者的興趣。在評估內部交易時,知道內部人員是否購買通常比知道他們是否出售更有益,因爲後者可能會有許多解釋。然而,當多名內部人士在特定時間內出售股票時,股東應該注意到這可能是一個紅色警示。

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

雖然我們認爲股東不應僅僅跟隨內部人士的交易,但邏輯告訴我們,應該注意內部人士是購買還是出售股票。

The Last 12 Months Of Insider Transactions At Genscript Biotech

Genscript Biotech的內幕交易最近12個月的情況

Over the last year, we can see that the biggest insider sale was by the insider, Hong Xin Guo, for HK$7.7m worth of shares, at about HK$22.73 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of HK$10.00. So it may not shed much light on insider confidence at current levels.

在過去的一年中,我們可以看到最大的內部銷售是由內部人員Hong Xin Guo銷售的,價值770萬港元,每股22.73港元左右。雖然內部銷售是一種負面因素,但對我們來說,如果股票以較低的價格出售,這是更爲負面的。好消息是,這個大的銷售價格遠高於當前價格10.00港元。因此,它可能不會在目前水平上揭示內部信心的情況。

In the last year Genscript Biotech insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

在過去一年中,Genscript Biotech的內部人員沒有購買任何公司股票。您可以在下面的圖表中查看過去一年的內部交易(由公司和個人)。通過點擊下面的圖表,您可以查看每個內部交易的詳細信息!

big
SEHK:1548 Insider Trading Volume July 13th 2024
SEHK:1548內部交易成交量 2024年7月13日

I will like Genscript Biotech better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

如果我看到一些大的內部買入,我會更喜歡Genscript Biotech。在等待的同時,可以查看這個免費的被低估和小盤股票列表,其中包含了相當多的最近內部交易。

Insider Ownership Of Genscript Biotech

Genscript Biotech的內部所有權

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Genscript Biotech insiders own 0.2% of the company, worth about HK$43m. But they may have an indirect interest through a corporate structure that we haven't picked up on. Whilst better than nothing, we're not overly impressed by these holdings.

檢驗公司領導人和其他股東之間的一致性的另一種方法是查看他們所擁有的股票數量。如果內部人員擁有公司的重要股份,這是一個好的跡象。從我們的數據來看,Genscript Biotech的內部人員擁有該公司的0.2%,價值約4300萬港元。但是,他們可能通過我們沒有發現的公司結構間接擁有利益。雖然不是很理想,但比沒有要好。

So What Do The Genscript Biotech Insider Transactions Indicate?

那麼Genscript Biotech的內幕交易表明什麼?

There haven't been any insider transactions in the last three months -- that doesn't mean much. Still, the insider transactions at Genscript Biotech in the last 12 months are not very heartening. But it's good to see that insiders own shares in the company. Of course, the future is what matters most. So if you are interested in Genscript Biotech, you should check out this free report on analyst forecasts for the company.

上個季度沒有任何內部交易,這並不意味着什麼。但是,最近12個月的Genscript Biotech公司內部交易並不令人鼓舞。但是,看到內部人員擁有該公司的股份是好事。當然,未來才是最重要的。因此,如果您對Genscript Biotech感興趣,應該查看該公司分析師預測的免費報告。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想查看其他公司——那些具有開多淨資產收益率和低負債的有趣公司的免費清單——那麼不要錯過這個機會。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關注內容?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋? 對內容感到擔憂? 請直接與我們聯繫。 或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論